NCT06467370View on ClinicalTrials.gov

A Real-world, Prospective Observational Study of Rimegepant ODT for the Acute Treatment of Migraine Attacks in Adults.

CompletedOBSERVATIONAL

Enrollment

342

Participants

Timeline

Start Date

July 2, 2024

Primary Completion Date

March 11, 2025

Study Completion Date

March 11, 2025

Conditions

Migraine

Trial Locations (1)

10001

Pfizer, New York

Sponsors

Lead Sponsor

All Listed Sponsors

collaborator

Aptar Digital Health

INDUSTRY

lead

Pfizer

INDUSTRY